Show simple item record

dc.contributor.authorPeces, Ramón
dc.contributor.authorMartínez-Ara, Jorge
dc.contributor.authorPeces, Carlos
dc.contributor.authorPicazo, Mariluz
dc.contributor.authorCuesta-López, Emilio
dc.contributor.authorVega, Cristina
dc.contributor.authorAzorín, Sebastián
dc.contributor.authorSelgas, Rafael
dc.contributor.otherUAM. Departamento de Medicinaes_ES
dc.contributor.otherInstituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ)es_ES
dc.date.accessioned2016-09-07T11:42:38Z
dc.date.available2016-09-07T11:42:38Z
dc.date.issued2011-05-05
dc.identifier.citationThe Scientific World Journal 11 (2011): 1041–1047en_US
dc.identifier.issn2356-6140 (print)es_ES
dc.identifier.issn1537-744X (online)es_ES
dc.identifier.urihttp://hdl.handle.net/10486/672733
dc.description.abstractWe report the case of a 38-year-old male with autosomal-dominant polycystic kidney disease (ADPKD) and concomitant nephrotic syndrome secondary to membranous nephropathy (MN). A 3-month course of prednisone 60 mg daily and losartan 100 mg daily resulted in resistance. Treatment with chlorambucil 0.2 mg/kg daily, low-dose prednisone, plus an angiotensin-converting enzyme inhibitor (ACEI) and an angiotensin II receptor blocker (ARB) for 6 weeks resulted in partial remission of his nephrotic syndrome for a duration of 10 months. After relapse of the nephrotic syndrome, a 13- month course of mycophenolate mofetil (MFM) 2 g daily and low-dose prednisone produced complete remission for 44 months. After a new relapse, a second 24-month course of MFM and low-dose prednisone produced partial to complete remission of proteinuria with preservation of renal function. Thirty-six months after MFM withdrawal, complete remission of nephrotic-range proteinuria was maintained and renal function was preserved. This case supports the idea that renal biopsy is needed for ADPKD patients with nephrotic-range proteinuria in order to exclude coexisting glomerular disease and for appropriate treatment/prevention of renal function deterioration. To the best of our knowledge, this is the first reported case of nephrotic syndrome due to MN in a patient with ADPKD treated with MFM, with remission of proteinuria and preservation of renal function after more than 10 years. Findings in this patient also suggest that MFM might reduce cystic cell proliferation and fibrosis, preventing progressive renal scarring with preservation of renal functionen_US
dc.description.sponsorshipThis work has been supported in part by grants from the Instituto de Salud Carlos III from Ministerio de Ciencia e Innovación (EC08/00236) and Programa Intensificación Actividad Investigadora (Agencia Laín-Entralgo/CM) to R.P.en_US
dc.format.extent8 pag.es_ES
dc.format.mimetypeapplication/pdfen
dc.language.isoengen
dc.publisherHindawi Publishing Corporationen_US
dc.relation.ispartofTheScientificWorldJournalen_US
dc.rights© 2011 with authoren
dc.subject.otherADPKDen_US
dc.subject.otherGlomerulonephritisen_US
dc.subject.otherMembranous nephropathyen_US
dc.subject.otherMycophenolate mofetilen_US
dc.subject.otherNephrotic syndromeen_US
dc.subject.otherProteinuriaen_US
dc.titleNephrotic syndrome and idiopathic membranous nephropathy associated with autosomal-dominant polycystic kidney diseaseen_US
dc.typearticleen
dc.subject.ecienciaMedicinaes_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1100/tsw.2011.94en
dc.identifier.doi10.1100/tsw.2011.94es_ES
dc.identifier.publicationfirstpage1041es_ES
dc.identifier.publicationlastpage1047es_ES
dc.identifier.publicationvolume11es_ES
dc.relation.projectIDGobierno de España. EC08/00236es_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
dc.rights.accessRightsopenAccessen
dc.authorUAMPicazo García, M. Luz (258664)
dc.authorUAMPeces Serrano, Ramón (274025)
dc.facultadUAMFacultad de Medicina
dc.institutoUAMInstituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record